The link between dopamine function and apathy in cannabis users: an [18F]-DOPA PET imaging study

  title={The link between dopamine function and apathy in cannabis users: an [18F]-DOPA PET imaging study},
  author={Michael A.P. Bloomfield and Celia J. A. Morgan and Shitij Kapur and H. Valerie Curran and Oliver D. Howes},
RationaleCannabis is the most widely used illicit drug in the world, and regular use has been associated with reduced motivation, i.e. apathy. Regular long-term cannabis use has been associated with reduced dopamine synthesis capacity. The mesolimbic dopaminergic system mediates the processing of incentive stimuli by modifying their motivational value, which in turn is modulated by endocannabinoid signalling. Thus, it has been proposed that dopaminergic dysfunction underlies the apathy… 
Deficits in striatal dopamine release in cannabis dependence
Evidence is provided that severe cannabis dependence—without the confounds of any comorbidity—is associated with a deficit in striatal dopamine release, which extends to other extrastriatal areas and predicts subclinical psychopathology.
A review of positron emission tomography studies exploring the dopaminergic system in substance use with a focus on tobacco as a co-variate
PET investigations from the last ten years that explore the dopaminergic system in tobacco, alcohol, stimulant, opiates, and cannabis addiction are summarized and the potential interactive effects of acute and chronic tobacco and substance co-use on the dopamine system are explored.
Cannabis-Induced Hypodopaminergic Anhedonia and Cognitive Decline in Humans: Embracing Putative Induction of Dopamine Homeostasis
Preliminary research suggests that it is possible to induce 'dopamine homeostasis,' that is, restore dopamine function with dopamine upregulation with the proposed compound and normalize behavior in chronic cannabis users with cannabis-induced hypodopaminergic anhedonia (depression) and cognitive decline.
The relation between dopamine D2 receptor blockade and the brain reward system: a longitudinal study of first-episode schizophrenia patients
In patients responding to a treatment-induced blockade of dopamine D2 receptors, the psychotic symptoms may be ameliorated by normalising salience abnormalities in the reward system.
Salience attribution and its relationship to cannabis-induced psychotic symptoms
Aberrant salience is positively associated with cannabis-induced psychotic symptom severity, but is not seen in cannabis users overall, consistent with the hypothesis that the link between cannabis use and psychosis involves alterations in salience processing.
Does cannabis affect dopaminergic signaling in the human brain? A systematic review of evidence to date
Cannabis Abusers Show Hypofrontality and Blunted Brain Responses to a Stimulant Challenge in Females but not in Males
The gender differences suggest that females are more sensitive than males to the adverse effects of cannabis in brain, and reduced baseline frontal metabolism is likely to contribute to relapse in CA.
Δ9-THC reduces reward-related brain activity in healthy adults.
These findings suggest that ∆9-THC dampens responses to both reward and loss feedback, which may reflect an "amotivational" state, and future studies are needed to determine generalizability.
Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders
Cannabis use diminishes some of the adverse effects of neurological and psychiatric disorders, however, chronic cannabis use may lead to cognitive impairments and dependence.


Dopaminergic Function in Cannabis Users and Its Relationship to Cannabis-Induced Psychotic Symptoms
Dopamine Release in Chronic Cannabis Users: A [11C]Raclopride Positron Emission Tomography Study
Delta-9-Tetrahydrocannabinol-Induced Dopamine Release as a Function of Psychosis Risk: 18F-Fallypride Positron Emission Tomography Study
This is the first study to demonstrate differential sensitivity to Δ9-THC in terms of increased endogenous dopamine release in individuals at risk for psychosis, using Positron Emission Tomography and 18F-fallypride.
Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study.
As in studies in unmedicated patients, presynaptic striatal dopamine dysfunction is present in medicated schizophrenic patients, adding further in vivo support for dopamine overactivity in the illness.
Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease
Does intravenous Δ9-tetrahydrocannabinol increase dopamine release? A SPET study
Findings do not support a central role for striatal DA in THC-elicited psychosis, and positive psychotic symptoms and DA release were unrelated.
The Reward Deficiency Syndrome: A Biogenetic Model for the Diagnosis and Treatment of Impulsive, Addictive and Compulsive Behaviors
In order to explain the breakdown of the reward cascade due to both multiple genes and environmental stimuli (pleiotropism) and resultant aberrant behaviors, Blum united this hypodopaminergic trait under the rubric of a reward deficiency syndrome.
Motivation, reward, and Parkinson’s disease: influence of dopatherapy